Bicocca Open Archive

Logo unimib boa
ZAMBELLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.769
NA - Nord America 2.835
SA - Sud America 1.889
EU - Europa 1.758
AF - Africa 111
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 18.370
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 6.009
US - Stati Uniti d'America 2.671
SG - Singapore 2.123
CN - Cina 1.738
BR - Brasile 1.514
HK - Hong Kong 1.137
RU - Federazione Russa 461
IT - Italia 342
KR - Corea 275
DE - Germania 255
AR - Argentina 140
SE - Svezia 118
ID - Indonesia 116
EC - Ecuador 86
FR - Francia 83
GB - Regno Unito 82
MX - Messico 82
IE - Irlanda 76
BD - Bangladesh 72
UA - Ucraina 71
IN - India 66
AT - Austria 62
FI - Finlandia 61
CA - Canada 51
ZA - Sudafrica 51
NL - Olanda 48
PY - Paraguay 47
IQ - Iraq 43
CO - Colombia 40
TR - Turchia 27
JP - Giappone 26
CL - Cile 21
RO - Romania 21
PK - Pakistan 19
VE - Venezuela 17
MA - Marocco 16
PL - Polonia 15
SA - Arabia Saudita 15
PE - Perù 14
UZ - Uzbekistan 14
ES - Italia 12
DK - Danimarca 11
TN - Tunisia 11
UY - Uruguay 10
KE - Kenya 9
CH - Svizzera 8
NP - Nepal 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
JO - Giordania 7
EG - Egitto 6
JM - Giamaica 6
MY - Malesia 6
OM - Oman 6
PH - Filippine 6
IL - Israele 5
KZ - Kazakistan 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
AU - Australia 4
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
IR - Iran 4
KW - Kuwait 4
AL - Albania 3
BE - Belgio 3
BG - Bulgaria 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
EU - Europa 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
LK - Sri Lanka 3
LT - Lituania 3
SV - El Salvador 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
CI - Costa d'Avorio 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
LB - Libano 2
LV - Lettonia 2
NO - Norvegia 2
PS - Palestinian Territory 2
PT - Portogallo 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
EE - Estonia 1
GR - Grecia 1
ME - Montenegro 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
Totale 18.365
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 1.911
Hanoi 1.551
Hong Kong 1.129
Singapore 1.026
Hefei 698
Ashburn 392
Seoul 275
Ann Arbor 258
Da Nang 184
Beijing 155
Haiphong 154
Los Angeles 147
Quận Bình Thạnh 140
Ha Long 127
Fairfield 126
Biên Hòa 118
Dallas 117
São Paulo 107
Woodbridge 107
Vũng Tàu 106
Ninh Bình 101
Buffalo 98
Quận Một 95
Chandler 94
Frankfurt am Main 94
Thái Nguyên 89
Bắc Ninh 80
Hải Dương 80
Milan 76
Dublin 75
Jakarta 74
Seattle 70
Can Tho 68
Moscow 66
Nuremberg 64
Houston 62
Wilmington 60
Rio de Janeiro 57
New York 56
Phủ Lý 55
Quận Phú Nhuận 53
Vinh 49
Santa Clara 44
Bắc Giang 43
Chicago 43
Lappeenranta 41
The Dalles 39
Dearborn 38
Jacksonville 38
Quận Tân Phú 37
Cambridge 36
Quận Sáu 35
Thái Bình 35
Guangzhou 34
Mexico City 34
Lang Son 32
Shanghai 32
Vĩnh Tường 31
Lấp Vò 30
Princeton 30
Quito 30
Vienna 30
Curitiba 28
Thu Dau Mot 28
Brasília 27
Hòa Bình 27
Kent 27
Paris 27
Munich 26
Nam Định 26
Điện Bàn 25
Quảng Ninh 24
Quận Năm 24
Belo Horizonte 23
Guayaquil 23
Cà Mau 22
Porto Alegre 22
Quận Bốn 22
Quận Hai 22
Bình Dương 21
Dong Ket 21
Phan Thiết 21
Quận Bảy 21
Uyen Hung 21
Campinas 20
Asunción 19
Tokyo 19
Bạc Liêu 18
Huế 18
Quảng Ngãi 18
Roșu 18
Boardman 17
Dhaka 17
Fortaleza 17
Johannesburg 17
Nanjing 17
Nha Trang 17
Quận Mười 17
Bình An 16
Guarulhos 16
Totale 11.965
Salva come PNG Salva come JPEG
Nome #
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 766
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 549
Short commentaries on data published by Petit et al. on locoregional risk after lipofilling in breast cancer patients 524
Analysis of SEMA6B gene expression in breast cancer: Identification of a new isoform 491
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 381
Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study 355
No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer 346
Targeting triple negative breast cancer: Is p53 the answer? 312
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression 312
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy 295
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 281
Management and Survival of Pleural Mesothelioma: A Record Linkage Study 269
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival 264
Retinoids and breast cancer: from basic studies to the clinic and back again 258
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 254
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 221
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. 210
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study 207
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 201
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study 192
Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway 183
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 175
ACUTE UPPER GASTROINTESTINAL BLEEDING (AUGB) IN ITALY: AN INTERIM ANALYSIS OF THE ORGANIZATIONAL ASPECTS CARING AN EVOLVING DISEASE 157
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors 156
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 152
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 152
A network-based data integration approach to support drug repurposing and multi-Target therapies in triple negative breast cancer 151
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems 144
Transfusion Strategy and Death Risk in Patients with Acute Non-Variceal Upper Gastro Intestinal Bleeding (NV-UGIB) in Italy: A Prospective Multicenter Observational Study 142
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 137
Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists 131
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial) 129
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry 129
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 128
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 122
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer 121
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy 121
Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer 120
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 120
Tyrosine kinase inhibitors and QTc intervals: A class effect 119
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 117
ONCO-i2b2: improve patients selection through CBR techniques with heterogeneous distance functions 116
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 116
Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations 113
BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork 112
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 110
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 109
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 104
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 104
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al 102
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 101
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 101
Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care 100
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 99
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates 98
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 97
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 96
The central role of pathology labs in breast cancer precision oncology: a call for action 94
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 91
i2b2 to optimize patients enrollment 87
Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) 86
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 86
Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study 85
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 85
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 84
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses 82
Correction to: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors (Journal of Endocrinological Investigation, (2023), 47, 2, (433-442), 10.1007/s40618-023-02174-5) 82
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 81
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 81
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 80
The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy 80
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis 79
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 77
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 77
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 77
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients 76
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 76
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 75
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy 75
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 74
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium 74
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 73
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review 73
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 73
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 73
Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer 71
Clinical Review on the Management of Breast Cancer Visceral Crisis 71
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis 70
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 69
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 69
The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort 69
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 69
International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality 68
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 67
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 66
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 66
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 65
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer 65
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds 64
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer - Immun-HER trial (GOIRC-01-2016) 63
Totale 14.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.251
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.251
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021246 0 0 0 0 0 22 18 37 35 49 21 64
2021/2022201 17 23 36 12 4 13 5 8 8 21 25 29
2022/2023357 35 123 36 22 22 49 0 22 22 1 15 10
2023/2024213 5 6 11 8 32 50 42 8 19 0 7 25
2024/20254.752 31 74 15 28 60 646 313 116 318 644 455 2.052
2025/202612.465 4.958 3.266 1.345 2.022 831 43 0 0 0 0 0 0
Totale 19.035